Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1887-1898

  Dionne, Craig A ^a   Camoratto, Anna Marie ^a   Jani, Jitesh P ^a   Emerson, Erling ^a   Neff, Nicola ^a   Vaught, Jeffry L ^a   Murakata, Chikara ^b   Djakiew, Daniel ^c   Lamb, John ^d   Bova, Steve ^d   George, Dan ^d   Isaacs, John T ^d  

^a CEPHALON INC   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 751; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; CELL CYCLE; CELL DEATH; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RATS; RATS, INBRED STRAINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031872458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Parker, S. L., Tong, T., Boden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 65: 5-27, 1996.
2. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, D. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
3. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C., and Isaacs, J. T. Implications of cell kinetic changes during the progression of human prostate cancer. Clin. Cancer Res., 1: 473-480, 1995.
4. Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin. Oncol., 15: 371-389, 1988.
5. Denmeade, S. R., Lin, X. S., and Isaacs, J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-265, 1996.
6. Segal, R. A., and Greenberg, M. E. Intracellular signaling pathways activated by neurotrophic factors. Annu. Rev. Neurosci., 19: 463-489, 1996.
7. MacGrogan, D., Despres, G., Romand, R., and Dicou, E. Expression of the β-nerve growth factor gene in male sex organs of the mouse, rat and guinea pig. J. Neurosci. Res., 28: 567-573, 1991.
8. MacGrogan, D., Saint-André, J. P., and Dicou, E. Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J. Neurochem., 59; 1381-1391, 1992.
9. Ip, N. Y., Ibanez, C. F., Nye, S. H., McClain, J., Jones, P. F., Gies, D. R., Belluscia, L., LeBeau, M. M., Squinto, S. P., Persson, H., and Yancopoulos, G. D. Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution and receptor specificity. Proc. Natl. Acad. Sci. USA, 89: 3060-3064, 1992.
10. Djakiew, D. Delsite, R., Pflug, B., Wrathall, J., Lynch, J. H., and Onoda, M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res., 51: 3304-3310, 1991.
11. Chung, L. W. K., Li, W., Gleave, M. E., Hsieh, J-T., Wu, H-C., Sikes, R. A., Zhau, H. E., Bandyk, M. G., Logothetis, C. J., Rubin, J. S., and von Exchenbach, A. C. Human prostate cancer model: roles of growth factors and extracellular matrices. J. Cell. Biochem., 16H: 99-105, 1992.
12. Pflug, B. R., Dionne, C., Kaplan, D. R., Lynch, J., and Djakiew, D. Expression of the Trk high affinity nerve growth factor receptor in the prostate. Endocrinology, 136: 262-268, 1995.
13. Shibayama, E., and Koizumi, H. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissue. Am. J. Pathol., 148: 1807-1818, 1996.
14. Camoratto, A. M., Jani, J. P., Angeles, T. S., Maroney, A. C., Sanders, C. Y., Murakata, C., Neff, N. T., Vaught, J. L., Isaacs, J. T., and Dionne, C. A. CEP-751 inhibits trk receptor kinase activity in vitro and exhibits anti-tumor activity. Int. J. Cancer, 72: 673-679, 1997.
15. Isaacs, J. T. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res., 49: 6290-6294, 1989.
16. Isaacs, J. T. Development and characteristics of the available animal model systems for the study of prostatic cancer. In: D. S. Coffey et al., eds., Current Concepts and Approaches to the Study of Prostate Cancer. Progress in Clinical and Biological Research, Vol. 20, pp. 513-576. Alan R. Liss, New York, 1987.
17. Bosland, M. C. et al. Recent advances in the development of animal and cell culture models for prostate cancer research. Urol. Oncol., in press, 1998.
18. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
19. Passiniti, A., Isaacs, J. T., Haney, J. A., Adler, S. W., Cujdik, T. J., Long, P. V., and Kleinman, H. K. Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int. J. Cancer, 51: 318-324, 1992.
20. Kyprianou, N., English, H., and Isaacs, J. T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3752, 1990.
21. DeKlerk, D. P., and Coffey, D. S. Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique: biomorphometrics. Invest. Urol., 16: 240-245, 1978.
22. Horigome, K. Pryor, J. C., Bullock, E. D., and Johnson, E. M., Jr. Mediator release from mast cells by nerve growth factor. Neurotrophin specificity and receptor mediation. J. Biol. Chem., 268: 14881-14887, 1993.
23. Herrmann, J. L., Menter, D. G., Hamada, J-i., Marchetti, D., Nakajima, M., and Nicolson, G. L. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol. Biol. Cell, 4: 1205-1216, 1993.
24. Berges, R. R., Furuya, Y., Remington, L., English, H. F., Jacks, T., and Isaacs, J. T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA, 90: 8910-8914, 1993.
25. Morton, R. A., Isaacs, J. T., and Isaacs, W. B. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. Prostate, 17: 327-336, 1990.
26. Barker, P. A., Lomen-Hoerth, C., Gensch, E. M., Meakin, S. O., Glass, D. J., and Shooter, E. M. Tissue-specific alternative splicing generates two isoforms of the trkA receptor. J. Biol. Chem., 268: 15150-15157, 1993.
27. Tsoulfas, P., Soppet, D., Escandon, E., Tessarollo, L., Mendoza-Ramirez, J-L., Rosenthal, A., Nikolics, K., and Parada, L. F. The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells. Neuron, 10: 975-990, 1993.
28. Berges, R. R., Furuya, Y., Remington, L. English, H. F., Jacks, T., and Isaacs, J. T. Cell proliferation, DNA repair and p53 function are not required for programmed cell death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA, 90: 8910-8914, 1993.
29. Stiens, R., and Helpap, B. Histologische und proliferationskinetische untersuchungen zum wachstum der rattenprostata in verschiedenen lebensaltern. Acta Anat., 109: 79-88, 1981.
30. Ichikawa, T., Lamb, J. B., Christensson, P. I., Hartley-Asp, B., and Isaacs, J. T. The antitumor effects of the quinoline-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res., 52: 3022-3028, 1992.
31. Vukanovic, J., and Isaacs, J. T. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499-1504, 1995.
32. DeCoster, R., Wouters, W., VanGinckel, R., End, D., Krekels, M., Coene, M-C., and Bowden, C. Experimental studies with liarozole (R 75 251): an antitumoral agent which inhibits retinoic acid breakdown. J. Steroid Biochem. Mol. Biol., 43: 197-201, 1992.
33. Dijkman, G. A., Van Moorselaar, R. J. A., Van Ginckel, R., Van Stratum, P., Wouters, L., Debruyne, F. M. J., Schalken, J. A., and DeCoster, R. Antitumoral effects of liarozole in androgen-dependent and independent R-3327 Dunning prostate adenocarcinomas. J. Urol., 151: 217-222, 1994.
34. Sloan, W. R., Heston, W. D. W., and Coffey, D. S. New model for studying the effects of cancer chemotherapeutic agents on the growth of the prostate gland. Cancer Chemother. Rep., 59: 185-194, 1975.
35. Martin-Zanca, D., Hughes, S. H., and Barbacid, M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (Lond.), 319: 743-748, 1986.
36. Pierotti, M. A., Bongarzone, I., Borrello, M. G., Greco, A., Pilotti, S., and Sozzi, G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer, 16: 1-14, 1996.
37. George, D. Suzuki, H. Bova, S., and Isaacs, J. T. Mutational analysis of the trkA gene in prostate cancer. Prostate, in press, 1998.
38. Coulier, F., Kumar, R., Ernst, M., Klein, R., Martin-Zanca, D., and Barbacid, M. Human trk oncogenes activated by point mutation, inframe deletion, and duplication of the tyrosine kinase domain. Mol. Cell. Biol., 10: 4202-4210, 1990.
39. Cordon-Cardo, C., Tapley, P., Jing, S., Nanduri, V., O'Rourke, E., Fabienne, L., Kovary, K., Klein, R., Jones, K. R., Reichardt, L. F., and Barbacid, M. The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell, 66: 173-183, 1991.
40. Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., and Barbacid, M. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell, 66, 395-403, 1991.
41. Lamballe, F., Klein, R., and Barbacid, M. TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell, 66: 967-979, 1991.
42. Powell, C. T., Fair, W. R., and Heston, W. D. W. Differential expression of protein kinase C isozyme messenger RNAs in Dunning R-3327 rat prostatic tumors. Cell Growth Differ., 5: 143-149, 1994.
43. Fudge, K., Wang, C. Y., and Stearns, M. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet derived growth factor α and β receptor expression in benign prostatic hyperplasias and Gleason graded human prostatic adenocarcinomas. Mod. Pathol., 7: 549-554, 1994.
44. Fudge, K., Bostwick, D. B., and Stearns, M. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia. Prostate, 29: 282-286, 1996.